U.S. Markets closed

MacroGenics, Inc. (MGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.60+0.39 (+2.27%)
At close: 04:00PM EST
17.60 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.21
Bid16.90 x 800
Ask18.34 x 1400
Day's Range16.94 - 17.73
52 Week Range15.77 - 36.48
Avg. Volume675,473
Market Cap1.057B
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-2.50
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.89

    Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...

    Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc..

  • GlobeNewswire

    MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following conferences in November and December 2021: Credit Suisse 30th Annual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview

  • Motley Fool

    MacroGenics (MGNX) Q3 2021 Earnings Call Transcript

    Good afternoon, and welcome to MacroGenics' conference call to discuss our third quarter 2021 financial and operational results. While we may elect to update these forward-looking statement statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change, except to the extent required by applicable law.